基线使用生物或靶向合成DMARDs与类风湿关节炎患者COVID-19严重程度的关联:COVID-19全球风湿病联盟医师注册研究结果
该研究基于COVID-19全球风湿病联盟医师注册数据,分析2869例类风湿关节炎患者基线使用不同b/tsDMARDs与COVID-19严重程度的关联。结果显示,与TNFi相比,利妥昔单抗(OR 4.15, 95%CI 3.16-5.44)和JAK抑制剂(OR 2.06, 95%CI 1.60-2.65)与更严重的COVID-19结局相关,而阿巴西普或IL-6抑制剂未见关联。
要点
- 利妥昔单抗与COVID-19严重程度升高相关(OR 4.15, 95%CI 3.16-5.44)。
- JAK抑制剂与COVID-19严重程度升高相关(OR 2.06, 95%CI 1.60-2.65)。
- 阿巴西普或IL-6抑制剂与COVID-19严重程度无关联。
核心结论
- 类风湿关节炎患者使用利妥昔单抗或JAK抑制剂较使用TNF抑制剂者COVID-19严重程度更高。
研究设计与样本
- 基于COVID-19全球风湿病联盟医师注册(2020年3月24日至2021年4月12日)的分析。
- 纳入2869例在COVID-19临床起病时使用b/tsDMARD的类风湿关节炎患者(平均年龄56.7岁,80.8%女性)。
主要发现
- 2869例中,237例使用阿巴西普、364例使用利妥昔单抗、317例使用IL-6抑制剂、563例使用JAK抑制剂、1388例使用TNF抑制剂。
- 总体613例(21%)住院,157例(5.5%)死亡。
- 与TNF抑制剂相比,利妥昔单抗(OR 4.15, 95%CI 3.16-5.44)和JAK抑制剂(OR 2.06, 95%CI 1.60-2.65)与更差的COVID-19严重程度相关。
- 阿巴西普或IL-6抑制剂与COVID-19严重程度无关联。
关键数值与推荐
- COVID-19严重程度有序结局:1无住院,2住院无需氧,3住院需氧/通气,4死亡。
- 采用有序logistic回归估计各药物类别相对于TNF抑制剂的OR(有序结局升高一级的比值比),并调整潜在基线混杂因素。
临床怎么用
- 对于使用利妥昔单抗或JAK抑制剂的类风湿关节炎患者,应优先采取风险缓解策略以降低COVID-19不良结局风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA). METHODS: We analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders. RESULTS: Of 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity. CONCLUSIONS: People with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.
引用
- Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021. PMID: 34049860. doi:10.1136/annrheumdis-2021-220418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。